(Q37625444)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880064%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

review article

1 reference

title

First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880064%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880064%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Wan-Teck Lim

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880064%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Tony Mok

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880064%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Ross A Soo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880064%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Benjamin O Anderson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880064%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Chih-Hsin Yang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880064%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Meilin Liao

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880064%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Peter Goldstraw

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880064%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Asian Oncology Summit

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880064%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

1 November 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880064%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

11 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880064%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880064%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880064%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

1102-1110

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880064%20AND%20SRC:MED&resulttype=core&format=json

The role of research in international tobacco control.

11 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Non-small cell lung cancer clinical practice guidelines in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Addressing resource allocation issues in recommendations from clinical practice guideline panels: suggestions from an American College of Chest Physicians task force

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: a quality and meta-analysis study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy [...]

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of r

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: a systematic review with meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Colorectal hepatic metastases: adjuvant chemotherapy and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

PET versus PET/CT dual-modality imaging in evaluation of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

The World Cancer Declaration: a roadmap for change

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Lung cancer management in limited resource settings: guidelines for appropriate good care.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Costs and health effects of breast cancer interventions in epidemiologically different regions of Africa, North America, and Asia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Economics of treatments for non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Cancer prevention in the political arena: the WHO perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

World Health Organization cancer priorities in developing countries.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Cancer control as a human right

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

The rising burden of cancer in the developing world

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Origins of the WHO Framework Convention on Tobacco Control.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Recommendations for a global core curriculum in medical oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Paying for modern cancer care--a global perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Information technology for health in developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970238-4

7 January 2021

10.1016/S1470-2045(09)70238-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19880064%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference